211 related articles for article (PubMed ID: 16980198)
1. Cortisol metabolism in hypertension.
Hammer F; Stewart PM
Best Pract Res Clin Endocrinol Metab; 2006 Sep; 20(3):337-53. PubMed ID: 16980198
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
Stewart PM
Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
[TBL] [Abstract][Full Text] [Related]
3. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].
Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW
Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595
[TBL] [Abstract][Full Text] [Related]
4. Apparent mineralocorticoid excess syndrome: an overview.
Palermo M; Quinkler M; Stewart PM
Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540
[TBL] [Abstract][Full Text] [Related]
5. Hypertension and the cortisol-cortisone shuttle.
Quinkler M; Stewart PM
J Clin Endocrinol Metab; 2003 Jun; 88(6):2384-92. PubMed ID: 12788832
[TBL] [Abstract][Full Text] [Related]
6. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
Morris DJ; Latif SA; Hardy MP; Brem AS
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the cancer-associated glucocorticoid system: key role of 11β-hydroxysteroid dehydrogenase type 2.
Cirillo N; Morgan DJ; Pedicillo MC; Celentano A; Lo Muzio L; McCullough MJ; Prime SS
Br J Cancer; 2017 Sep; 117(7):984-993. PubMed ID: 28797028
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Stewart PM; Toogood AA; Tomlinson JW
Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
[TBL] [Abstract][Full Text] [Related]
9. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P; Lovati E; Frey FJ
J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Rauz S; Cheung CM; Wood PJ; Coca-Prados M; Walker EA; Murray PI; Stewart PM
QJM; 2003 Jul; 96(7):481-90. PubMed ID: 12881590
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Biochemical, and Genetic Characteristics of "Nonclassic" Apparent Mineralocorticoid Excess Syndrome.
Tapia-Castillo A; Baudrand R; Vaidya A; Campino C; Allende F; Valdivia C; Vecchiola A; Lagos CF; Fuentes CA; Solari S; Martínez-Aguayo A; García H; Carvajal CA; Fardella CE
J Clin Endocrinol Metab; 2019 Feb; 104(2):595-603. PubMed ID: 30239803
[TBL] [Abstract][Full Text] [Related]
12. Cortisol as a mineralocorticoid in human disease.
Stewart PM
J Steroid Biochem Mol Biol; 1999; 69(1-6):403-8. PubMed ID: 10419018
[TBL] [Abstract][Full Text] [Related]
13. Prenatal overexposure to glucocorticoids programs renal 11β-hydroxysteroid dehydrogenase type 2 expression and salt-sensitive hypertension in the rat.
Tang JI; Kenyon CJ; Seckl JR; Nyirenda MJ
J Hypertens; 2011 Feb; 29(2):282-9. PubMed ID: 21045727
[TBL] [Abstract][Full Text] [Related]
14. The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension.
van Uum SH; Hermus AR; Smits P; Thien T; Lenders JW
Cardiovasc Res; 1998 Apr; 38(1):16-24. PubMed ID: 9683905
[TBL] [Abstract][Full Text] [Related]
15. The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P
Biochim Biophys Acta; 2010 Dec; 1802(12):1178-87. PubMed ID: 19909806
[TBL] [Abstract][Full Text] [Related]
16. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.
Campino C; Carvajal CA; Cornejo J; San Martín B; Olivieri O; Guidi G; Faccini G; Pasini F; Sateler J; Baudrand R; Mosso L; Owen GI; Kalergis AM; Padilla O; Fardella CE
Endocrine; 2010 Feb; 37(1):106-14. PubMed ID: 19882252
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Frey FJ; Odermatt A; Frey BM
Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):451-8. PubMed ID: 15199296
[TBL] [Abstract][Full Text] [Related]
18. Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension.
van Uum SH; Lenders JW; Hermus AR
Semin Vasc Med; 2004 May; 4(2):121-8. PubMed ID: 15478032
[TBL] [Abstract][Full Text] [Related]
19. Modulation of 11β-hydroxysteroid dehydrogenase functions by the cloud of endogenous metabolites in a local microenvironment: The glycyrrhetinic acid-like factor (GALF) hypothesis.
Morris DJ; Brem AS; Odermatt A
J Steroid Biochem Mol Biol; 2021 Nov; 214():105988. PubMed ID: 34464733
[TBL] [Abstract][Full Text] [Related]
20. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Draper N; Stewart PM
J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
